Lago SYA, Labrada TDÁ, Breijo PA, Lago SD, Sosa GD

Language: Spanish
References: 13
Page:
PDF size: 225.08 Kb.

ABSTRACT

Introduction: among Théo clinical conditions that cause cardiovascular risk, type 2 diabetes mellitus stands out, and macrovascular complications in these patients are the main cause of morbidity and mortality.
Objective: to identify the possible association betei risk factors and the development of macrovascular lesions in patients with type 2 diabetes.
Methods: an analytical case-control study (1: 2 ratio) was carried out in patients with type 2 DM admitted to the Diabetic Care Center (CAD) of Bayamo, Granma province, in the period between 2017 and 2019.
Results: the analysis of the qualitativos variables, the non-control of diabetes was the most important factor (OR = 13.05; CI = 5.750-29.633; p = 0.000) followed by pathological electrocardiogram (OR = 10.61; CI = 4.269 -26.396; p = 0.000). Univariate analysis of quantitative variables, age over 55 years and arterial hypertension regardless of type (systolic or diastolic) were the most frequent factors. The multivariate analysis through a binary logistic regressos, the most important factor was the non-control of diabetes mellitus (CI = 6.758-27.639; p = 0.00) followed by the metabolic syndrome (OR = 15.837; CI = 2.869- 17,424; p = 0.00) uncontrolled hypertension (OR = 11.319; CI = 2.016-63.542; p = 0.000).
Conclusions: the most relevant risk factors for the development of cardiovascular disease in patients with type 2 diabetes were uncontrolled diabetes mellitus, metabolic syndrome and uncontrolled arterial hypertension.

REFERENCES

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes care 2005; 28(37): 5-10.

2. American Diabetes Association. Classification and diagnosis of diabetes: standards of medical care in diabetes 2019. Diabetes Care 2019; 42(Supplement 1): 13-28.

3. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37(29): 2315-2381.

4. Ritsinger V, Hero C, Svensson AM, Saleh N, Lagerqvist B, Eeg-Olofsson K, et al. Characteristics and Prognosis in Women and Men With Type 1 Diabetes Undergoing Coronary Angiography: A Nationwide Registry Report. Diabetes Care 2018; 41(4): 876-83.

5. Furst J. Retrospective study finds that cancer drug also lowers blood glucose. Mayo Clinic. [Internet]. 2021 [citado 2/4/2021]. Disponible en: https://www.sciencedaily.com/releases/2021/11/211109080904.htm

6. MINSALUD. Análisis de la situación de salud en Colombia (ASIS). [Internet]. Bogotá: Dirección de Epidemiología y Demografía; 2018. [citado 5/2/2021]. Disponible en: https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/PSP/asis-colombia-2016.pdf

7. Misterio de Salud Pública. Anuario Estadístico de Salud de Cuba 2019. [Internet]. La Habana: MINSAP; 2020. [citado 2/4/2020]. Disponible en: https://temas.sld.cu/estadisticassalud/2020/05/13/publicado-el-anuario-estadistico-de-salud-2019/ 8. Gnatiuc L, Herrington WG, Halsey J, Tuomilehto J, Fang X, Kim HC, et al. Sex-specific relevance of diabetes to occlusive vascular and other mortality: a collaborative meta-analysis of individual data from 980 793 adults from 68 prospective studies. The lancet Diabetes & Endocrinology 2018; 6(7): 538-46. 9. Consentino F, Grant P, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. Guía ESC 2019 sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes (EASD). Revista Española de Cardiología 2020; 73(5): 404.e1-404.e59.

8. Lara-O’Farrill LC, O’Farrill Fernández LA, Martínez de Santelices Cuervo A. Interacción Genoambiente en la génesis de la DM2. Acta Médica del Centro. [Internet]. 2017 [citado 5/2/2021]; 11(4). Disponible en: http://www.revactamedicacentro.sld.cu/index.php/amc/article/view/867/1099

9. Care D. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes 2018. Diabetes Care 2018; 41(Suppl. 1): 105–18.

10. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. The Lancet 2010; 375: 2215–22.

11. Salinero-Fort MA, Burgos-Lunar C, Lahoz C, Mostaza JM, Abánades Herranz JC, Laguna-Cuesta F, et al. Performance of the Finnish Diabetes Risk Score and a Simplified Finnish Diabetes Risk Score in a Community Based. The SPREDIA-2 Study. PLoS ONE 2016; 11(7): e0158489.

12. Álvarez Aliaga A, González Aguilera JC, Maceo Gómez LR. Factors associated to hypertensive heart disease development: a prospective cohort study in Bayamo, Cuba. Medwave 2016; 16(6): e6492.

13. Valdés Ramos ER, Espinosa Benítez Y. Factores de riesgo asociados con la aparición de enfermedad arterial periférica en personas con diabetes mellitus tipo 2. Rev Cubana de Med 2013; 52(1): 4-13.